[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lennox-gastaut-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lennox-gastaut-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,74,101,124,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100444345","phase-3-an-efficacy-and-safety-study-of-clemizole-hcl-in-patients-with-lennox-gastaut-syndrome-100444345",false,"NCT05066217","An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome","Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome","Key Inclusion Criteria:\n\n1. Males or females, ages ≥2 to ≤55 years, at the time of Screening.\n2. Participant\u002Fparent\u002Flegal authorized representative (LAR) willing and able to give written informed consent\u002Fassent.\n3. Diagnosis of LGS, including:\n\n   * Evidence of at least one type of countable major motor seizure.\n   * History of electroencephalogram (EEG) consistent with LGS (abnormal background activity, and one of the following: 1) slow spike-wave discharges \\[\\\u003C2.5 Hz\\], or 2) paroxysmal fast activity during sleep).\n   * Abnormal cognitive development.\n   * Onset of seizures at 11 years of age or younger.\n\nKey Exclusion Criteria:\n\n1. Known sensitivity, allergy, or previous exposure to clemizole HCl.\n2. Known history of long QT syndrome or any significant history of a serious abnormality of the electrocardiogram (ECG) (e.g., recent myocardial infarction, clinically significant arrhythmia).\n3. Family history of sudden cardiac death, unexplained death, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member.\n4. Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or progressive central nervous system disease, metabolic illness, recent anoxic episode within the last 6 months requiring resuscitation, or progressive degenerative disease or any other condition, which in the opinion of the investigator, could affect seizure control.\n5. Epilepsy surgery planned during the study or epilepsy surgery within 6 months prior to Screening.\n6. Concomitant use of fenfluramine.\n7. Prior or concomitant use of lorcaserin.","ALL","2 Years","55 Years",{"count":20,"type":21},260,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).",[27],"Lennox Gastaut Syndrome",[27,29,30,31,32],"Lennox-Gastaut Syndrome","LGS","Clemizole HCl","Seizure","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2025-04-09",{"date":41,"type":21},"2029-11-01",{"name":43,"class":44},"Epygenix","INDUSTRY",26,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100546943","phase-2-bmb-101-in-absence-epilepsy-and-dee-100546943","NCT06401538","BMB-101 in Absence Epilepsy and DEE","An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).","Inclusion Criteria:\n\n1. Subjects must have a diagnosis of Absence Epilepsy with or without eyelid myoclonia (Jeavons Syndrome) or a diagnosis of Developmental and Epileptic Encephalopathy (DEE) such as Dravet syndrome or Lennox-Gastaut syndrome or other DEE.\n2. Subjects with Absence must experience at least 4 episodes of 3-4\u002Fsecond SWD lasting at least 3 seconds each in a 24 hour EEG during the baseline period. Those with DEE must have a typical EEG pattern for DEE on routine EEG and experience at least 4 seizures during the 4 week baseline period prior to BMB-101 administration.\n3. Subjects can be male or female ages 18-65 inclusive at time of baseline.\n4. Subject must have tried at least one anti-seizure medication at a recommended dose and duration and must be on a stable dose on their current anti-seizure medications for at least 4 weeks prior to baseline and remain stable throughout the study.\n5. Subjectis willing and able to be compliant with diary completion, visit schedule, and study drug accountability.\n6. Female subjects of childbearing potential must have a negative urine pregnancy test at baseline. Subjects of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control, which includes abstinence, while in this study and for 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, pulmonary hypertension, myocardial infarction or stroke, or clinically significant structural cardiac abnormality.\n2. Subject has moderate or severe hepatic impairment. Asymptomatic subjects with mild hepatic impairment (elevated liver enzymes \\\u003C 3x upper limit of normal (ULN) and\u002For elevated bilirubin \\\u003C2x ULN) may be entered into the study after review and approval by the Medical Monitor in conjunction with the sponsor, in consideration of comorbidities and concomitant medications.\n3. Subject has severe renal impairment (estimated glomerular filtration rate \\\u003C30mL\u002Fmin\u002F1.73m2)\n4. Clinically significant ECG abnormality such as QTcF \\>450 msec (males) or \\>470 msec (females)\n5. Subject is receiving concomitant therapy with: fenfluramine, lorcaserin, monoamine-oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants or other serotonergic agonists or antagonists (antipsychotics).\n6. Subject is currently receiving an investigational medicinal product.\n7. Subject has participated in another clinical trial within the past 30 days (calculated from that study's last scheduled visit). Participation in non-treatment trials will be reviewed by the medical monitor.\n8. Subject has a history of drug or alcohol abuse within the last 12 months or a positive urine drug screen (with the exception of cannabinoids).\n9. A current C-SSRS score of 4 or 5 at baseline or history of suicide attempt at any time during the past year\n10. Subject has a clinically significant condition or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Baseline Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.","18 Years","65 Years",{"count":56,"type":21},20,[58],"PHASE2","The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering\u002Fwashout periods, and then a 1 month follow-up period. There will be 6 clinic visits.",[61,62,63,27],"Absence Epilepsy","Jeavons Syndrome","Dravet Syndrome","2025-08-07",{"date":66,"type":37},"2025-08-12",{"date":68,"type":37},"2024-12-05",{"date":70,"type":21},"2025-11-30",{"name":72,"class":44},"Bright Minds Biosciences Pty Ltd",5,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100456133","phase-3-investigate-efficacy-and-safety-of-carisbamate-as-adjunctive-treatment-for-seizures-associated-with-lgs-in-children-and-adults-100456133","NCT05219617","Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults","A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension","Inclusion Criteria:\n\n1. Subject must have a documented history of Lennox-Gastaut syndrome by:\n\n   1. Evidence of more than one type of seizure, of which at least one should be an atonic or tonic seizure\n   2. History of an electroencephalogram (EEG) reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow, spike and wave pattern \\\u003C3.0 Hz)\n   3. History of developmental delay\n2. Male or female subjects\n3. Subjects must be age 4-55 years at the time of consent\u002Fassent\n4. Must have been \\\u003C11 years old at the onset of LGS\n5. Subjects must have experienced at least 2 drop seizures with potential to fall (tonic, atonic, tonic-clonic) during the 4-week Baseline period preceding randomization (minimum of 4 drop seizures in the first two weeks and 4 in the last two weeks). Drop seizures are defined as a seizure involving the entire body, trunk, or head that led or could have led to a fall, injury, slumping in a chair, or hitting the subject's head on a surface. All drop seizure types must be countable (either as isolated seizures or as countable isolated seizures in a cluster).\n6. Subjects must have been receiving 1 to 4 concomitant anti-seizure medications (ASMs) at a stable dose for at least 4 weeks before Visit 1\n7. If not taking Epidiolex, subjects may take other approved cannabidiol or over the counter cannabidiol products. If taking cannabidiol other than Epidiolex, consult Medical Monitor to determine if it counts as a concomitant ASM.\n8. Dietary therapy and any CNS stimulator settings must be stable for 4 weeks prior to baseline and maintain stable regimen throughout the study. The dietary therapy and CNS stimulators are not counted as an ASM.\n9. Parents or caregivers must be able to keep accurate seizure diaries\n10. Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of birth control during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study, if able.\n11. Subject and\u002For caregiver(s)\u002Flegal representative must be willing and able to give informed assent\u002Fconsent for participation in the study\n12. Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements\n13. History of COVID-19 vaccination is permitted\n\nExclusion Criteria:\n\n1. Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation, unless there is a progressive brain tumor\n2. Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the subject's safety or study conduct\n3. Subjects who were on adrenocorticotropic hormone (ACTH) therapy in the 6 months prior to baseline\n4. Subject on dietary therapy for less than 4 weeks prior to screening visit (Visit 1) or suffers from frequent stooling\n5. Current use of felbamate with less than 18 months of continuous exposure\n6. Concomitant use of vigabatrin: subjects who took vigabatrin in the past must be discontinued for at least 5 months before Visit 1 and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test, if able.\n7. Subject who had a history of hypoxia which needed emergency resuscitation within 12 months prior to baseline\n8. Status epilepticus within 12 weeks prior to Visit 1\n9. Any clinically significant illness (including COVID-19) in the 4 weeks prior to Visit 1, as evaluated by the Investigator\n10. Subject has clinically significant abnormal laboratory values, in the investigator's opinion, at Visit 1 or time of randomization (Visit 2)\n11. Subject has a history of any serious drug-induced hypersensitivity, e.g., toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms \\[DRESS\\]) or any drug-related rash requiring hospitalization\n12. Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Responsive Neurostimulator System (RNS) or other neurostimulation for epilepsy device implanted or activated \\\u003C5 months year prior to enrollment. Stimulation parameters that have been stable for \\\u003C4 weeks, or Battery life of unit not anticipated to extend for duration of trial.\n13. Subject is pregnant, may be pregnant, lactating or planning to be pregnant\n14. Any suicidal ideation with intent, with or without a plan within 6 months before Visit 2 (i.e., answering \"Yes\" to questions 4 or 5 in the Suicidal Ideation section of the age- specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated\n15. Any suicidal behavior within 2 years before Visit 2 (i.e., answering YES to any question in the Suicidal behavior section of the age-specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated.\n16. Evidence of significant active hepatic disease. Stable elevations of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) due to concomitant medication(s) will be allowed if they are \\\u003C3 x ULN\n17. Subject with total bilirubin \\[TBL\\] \\>2 x ULN (except for Gilbert's syndrome).\n18. Active viral hepatitis (B or C) as demonstrated by positive serology at the Screening visit (Visit 1)\n19. History of positive antibody\u002Fantigen test for human immunodeficiency virus (HIV)\n20. If taking Epidiolex, subject may not use other approved cannabidiol or over the counter cannabidiol products\n21. Scheduled for epilepsy-related surgery, VNS insertion, or any other stimulators\u002Fsurgery during the projected course of the study\n22. Subject who has taken or used any investigational drug or device in the 4 weeks prior to the screening visit (Visit 1)\n23. Concomitant use of medications known to be strong inducers of cytochrome P450 (CYP3A) including, but not limited to: phenobarbital, phenytoin, carbamazepine, primidone, rifampin, troglitazone, St. John's Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin\n24. Evidence of cardiac disease, including unstable angina, myocardial infarction, within the past 2 years, uncontrolled heart failure, major arrhythmias, congenital short QT syndrome\n25. Subject with a short QTc interval (\\\u003C340 msec) or long QTc interval (\\>460 msec) as confirmed by a repeated electrocardiogram (ECG)\n26. Benzodiazepine rescue administered on average more than once a week in the month before Visit 1\n27. Previous exposure to carisbamate or sensitivity\u002Fallergy to components of the oral suspension.","4 Years",{"count":83,"type":21},252,[24],"The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).",[87,27],"Seizures",[87,27,89,90],"Pediatrics","Adults","2025-07-21",{"date":93,"type":37},"2025-07-24",{"date":95,"type":37},"2022-04-28",{"date":97,"type":21},"2028-12",{"name":99,"class":44},"SK Life Science, Inc.",71,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":121,"locationsCount":123},"100345493","an-extended-access-program-eap-for-participants-who-have-completed-rufinamide-study-e2080-g000-303-100345493","NCT03778424","An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303","An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome","Inclusion Criteria:\n\n* Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.\n\nExclusion Criteria:\n\n* Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.","EXPANDED_ACCESS","This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.",[27],[112,113,114,115,87,116],"Central Nervous System","E2080","Rufinamide","Epilepsy","Brain Diseases","AVAILABLE","2025-07-14",{"date":120,"type":37},"2025-07-17",{"name":122,"class":44},"Eisai Inc.",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":4,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":143,"locationsCount":145},"100527584","intermediate-size-expanded-access-protocol-eap-for-lp352-100527584","NCT06149663","Intermediate-Size Expanded Access Protocol (EAP) for LP352","Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)","Inclusion Criteria:\n\n1. Participant and\u002For participant's legally authorized representative is willing and able to provide a written informed consent or assent form before participation in this EAP. An assent should be obtained from the patient, if possible. Assent must be obtained for adolescent EAP patients (\\\u003C18 years of age) as required by local regulations.\n2. Participant with DEE who has successfully completed an LP352 Clinical Trial.\n3. Participant currently has clinical benefit from LP352 treatment, as assessed by their Treating Physician.\n4. Participant currently tolerates LP352 treatment and has no safety issue which would prevent continued treatment.\n\nExclusion Criteria:\n\n1. Participant was discontinued from an LP352 Clinical Trial for any reason.\n2. Any serious and\u002For unstable new medical condition, psychiatric disorder, or other conditions at the time of transition to this EAP that could interfere with patient's safety, obtaining informed consent, assent, or compliance to this EAP protocol, in the opinion of the Treating Physician.","This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.",[63,27,133],"Developmental and Epileptic Encephalopathies",[135,136,63,137,27,138,139],"CDKL5 deficiency disorder","developmental and epileptic encephalopathy","epilepsy","treatment resistant epilepsy","tuberous sclerosis complex","2025-01-20",{"date":142,"type":37},"2025-01-22",{"name":144,"class":44},"Longboard Pharmaceuticals",22,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":172},"100468057","comparative-effectiveness-of-palliative-surgery-versus-additional-anti-seizure-medications-for-lennox-gastaut-syndrome-100468057","NCT05374824","Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome","Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome - PCORI","SOM-L","Inclusion Criteria:\n\nPatients with the diagnosis of Lennox Gastaut syndrome with medical records at the seven plus eleven pediatric centers\n\nExclusion Criteria:\n\nPatients without Lennox Gastaut Syndrome","26 Years",{"count":156,"type":21},4680,"OBSERVATIONAL","Lennox-Gastaut syndrome is a serious and rare form of epilepsy that begins in infancy and early childhood. Seizures and their consequences need medical attention, emergency encounters, and hospitalizations. Seizures disrupt home life for the patient and for family. Lennox-Gastaut syndrome is typically accompanied by disabilities in motor, communication, eating, and other skills needed for daily function.\n\nLennox-Gastaut syndrome (LGS) has no cure. Although current treatments may help reduce the number of seizures, none are expected to eliminate them entirely; these treatments are palliative. The main treatments include anti-seizure medications and some surgical approaches, including the implantation of a vagus nerve stimulator (a pacemaker-like generator implanted in the chest wall and programmed by a physician to stimulate the vagus nerve in the neck) and corpus callosotomy (cutting through the band of fibers that connect the two sides of the brain). While both types of treatment (medications and surgeries) produce some benefit by reducing how often the seizures occur, both also have some risks. All medications can, in some patients, produce moderate to severe side effects. This is true of anti-seizure medications. Most patients with LGS take several anti-seizure medications at a time. Surgeries can also have associated risks and is additionally stressful for parents and family members. Currently, there is no strong evidence to support parents and physicians in deciding which type of treatment (more medicines or surgery) will be most successful for a child with LGS, and whether one or the other approach may lessen the toll that seizures take on a child's development and ability to function.\n\nThis study has two components. It will engage a network of seven pediatric hospitals in the United States where children with Lennox-Gastaut syndrome are cared for and determine whether seizure-related emergency department visits and hospitalizations are more likely to be reduced following the use of additional medications or adding palliative surgery to existing medications. The investigators will determine whether medical versus surgical treatment is more likely to lessen some of the developmental and functional difficulties that affect patients with LGS. The study will also determine whether starting therapies at a younger versus older age makes a difference.\n\nThe second component of the study will provide a description of the use of surgical versus medical treatment approaches across 18 pediatric hospitals in the United States (seven plus 11 centers). The investigators will describe how treatments differ across hospitals and over time.\n\nThe results from this study will help parents and providers make more informed choices about treatment for children with Lennox-Gastaut syndrome and will highlight areas for improvement in providing the best possible health care for this severe, lifelong disorder.",[27],[137,161],"seizure","2024-07-12",{"date":164,"type":37},"2024-07-16",{"date":166,"type":37},"2022-04-01",{"date":168,"type":21},"2025-08-31",{"name":170,"class":171},"Ann & Robert H Lurie Children's Hospital of Chicago","OTHER",4]